共 50 条
- [31] REDUCTION IN THE RATE AND RISK OF MODERATE OR SEVERE EXACERBATIONS WITH ONCE-DAILY INDACATEROL/GLYCOPYRRONIUM COMPARED WITH TWICE-DAILY SALMETEROL/FLUTICASONE IN A SUBSET OF GOLD GROUP D COPD PATIENTS WITH A HISTORY OF ≥2 EXACERBATIONS OR 1 HOSPITALIZATION: THE FLAME STUDYRESPIROLOGY, 2018, 23 : 74 - 74Banerji, D.Vogelmeier, C.Wedzicha, J.Donohue, J.Fucile, S.Yadao, A.Ayers, T.Thach, C.Olsson, P.Fowlertaylor, A.Fogel, R.Patalano, F.
- [32] Once-Daily Indacaterol/glycopyrronium Reduces The Rate And Risk Of Moderate Or Severe Exacerbations Compared With Twice-Daily Salmeterol/fluticasone In A Subset Of Gold Group D COPD Patients With A History Of ≥2 Exacerbations Or 1 Hospitalization: The Flame StudyAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195Vogelmeier, C.Wedzicha, J.Donohue, J.Fucile, S.Yadao, A.Ayers, T.Thach, C.Taylor, A. FowlerFogel, R.Patalano, F.Banerji, D.
- [33] ONCE-DAILY CO-ADMINISTRATION OF GLYCOPYRRONIUM AND INDACATEROL IMPROVES LUNG FUNCTION AND SYMPTOMS IN PATIENTS WITH COPD VERSUS INDACATEROL ALONE: THE GLOW6 STUDYRESPIROLOGY, 2014, 19 : 117 - 117Vincken, W.Goyal, P.Jack, D.Henley, M.Mcbryan, D.
- [34] COMPARISON OF THE EFFICACY AND SAFETY OF ONCE-DAILY GLYCOPYRRONIUM WITH BLINDED TIOTROPIUM IN PATIENTS WITH COPD: THE GLOW5 STUDYRESPIROLOGY, 2013, 18 : 30 - 30Chapman, Kenneth R.Beeh, KaiBateman, Eric D.Beier, JuttaD'Urzo, AnthonyNutbrown, RobertChen, HungtaHenley, MichelleOverend, TimD'Andrea, Peter
- [35] Once-Daily QVA149 Demonstrates Superior Improvements in Patient-Reported Dyspnea Compared to Tiotropium in Patients With Moderate-to-Severe COPD: The BLAZE StudyCHEST, 2014, 145 (03)D'Urzo, AnthonyMahler, DonaldWorth, HeinrichWhite, TracyAlagappan, VijayChen, HungtaKulich, KarolyGallagher, NicolaBanerji, Donald
- [36] Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE studyEUROPEAN RESPIRATORY JOURNAL, 2013, 42Mahler, Donald A.Decramer, MarcD'Urzo, AnthonyWorth, HeinrichWhite, TracyAlagappan, VijayChen, HungtaKulich, KarolyGallagher, NicolaBanerji, Donald
- [37] Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK studyEUROPEAN RESPIRATORY JOURNAL, 2013, 42Wedzicha, Jadwiga A.Decramer, MarcFicker, Joachim H.FowlerTaylor, AngelD'Andrea, PeterArrasate, ChristieChen, HungtaBanerji, Donald
- [38] Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME studyEUROPEAN RESPIRATORY JOURNAL, 2016, 48Fogel, RobertChapman, Kenneth R.Vogelmeier, Claus F.FowlerTaylor, AngelAyers, TimThach, ChauWhelan, SarahClerkin, KarynPatalano, FrancescoBanerji, Donald
- [39] Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥ 1 exacerbation in the previous year: The FLAME studyEUROPEAN RESPIRATORY JOURNAL, 2016, 48Wedzicha, JadwigaVogelmeier, Claus F.Ayers, TimFowlerTaylor, AngelThach, ChauOlsson, PetterFogel, RobertPatalano, FrancescoBanerji, Donald
- [40] DUAL-BRONCHODILATION WITH ONCE-DAILY QVA149 IN PATIENTS WITH MODERATE-TO-SEVERE COPD: OVERVIEW OF THE IGNITE PROGRAMTHORAX, 2013, 68 : A183 - A184Price, D.Mezzi, K.Fedele, M. J.Chen, H.Banerji, D.